Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMU3D2O)

• Drug Name: BARETTIN Drug Info
• Synonyms: (-)-Barettine; GBB 1-Z; 104311-70-8; AC1O5Z3U; 606933-69-1

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 11177588
  CAS Number: CAS 104311-70-8
  TTD Drug ID: DMU3D2O

Molecule-Related Drug Atlas

Drug(s) Targeting 5-HT 2A receptor (HTR2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[2]
ZOTEPINE	DMF3VXA	Anxiety disorder	6B00-6B0Z	Approved	[3]
Iloperidone	DM6AUFY	Schizophrenia	6A20	Approved	[4]
Flibanserin	DM70DTN	Depression	6A70-6A7Z	Approved	[5]
Lurasidone hydrochloride	DMCVPXO	Schizophrenia	6A20	Approved	[6]
Aniracetam	DMOIFW0	Cerebrovascular ischaemia	8B1Z	Approved	[7]
lumateperone tosylate	DMQ8HOJ	Schizophrenia	6A20	Approved	[8]
Sarpogrelate	DMGLP6S	Diabetic complication	5A2Y	Approved	[9]
Pimavanserin	DMR7IVC	Parkinson disease	8A00.0	Approved	[10]
Zicronapine	DMP8ESD	Schizophrenia	6A20	Phase 3	[11]

Drug(s) Targeting 5-HT 4 receptor (HTR4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisapride	DMY7PED	Gastroesophageal reflux disease	DA22.Z	Approved	[12]
Tegaserod	DM3XYD1	Irritable bowel syndrome	DD91.0	Approved	[13]
R0-93877	DMM4U9G	Constipation	DD91.1	Approved	[14]
HTF 919	DM78G6F	Constipation	DD91.1	Approved	[15]
Mosapride	DM2VOQ3	N. A.	N. A.	Phase 4	[16]
Renzapride	DM7HQNX	Irritable bowel syndrome	DD91.0	Phase 3	[17]
Lintopride	DMSHGWN	Nausea	MD90	Phase 2	[18]
TD-8954	DM3C9NV	Gastrointestinal disease	DE2Z	Phase 2	[19]
SB-207266A	DM27KFY	Irritable bowel syndrome	DD91.0	Phase 2	[14]
YKP-GI	DM740LV	Constipation	DD91.1	Phase 2	[20]

Drug(s) Targeting 5-HT 2C receptor (HTR2C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[2]
Lorcaserin	DMG6OYJ	Obesity	5B81	Approved	[21]
Tramadol	DMRQD04	Osteoarthritis	FA00-FA05	Approved	[22]
Mirtazapine	DML53ZJ	Depression	6A70-6A7Z	Approved	[23]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[24]
Methysergide	DM1EF73	Migraine	8A80	Approved	[25]
Eltoprazine	DMW6C81	Attention deficit hyperactivity disorder	6A05.Z	Phase 3	[26]
M100907	DM7ZFBA	Sleep-wake disorder	7A00-7B2Z	Phase 3	[27]
SR46349B	DM1ODMR	Primary insomnia	7A00	Phase 3	[28]
Vabicaserin	DM9GZW6	Psychotic disorder	6A20-6A25	Phase 2	[29]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 2A receptor (HTR2A)	TTJQOD7	5HT2A_HUMAN	Inhibitor	[1]
5-HT 2C receptor (HTR2C)	TTWJBZ5	5HT2C_HUMAN	Inhibitor	[1]
5-HT 4 receptor (HTR4)	TT07C3Y	5HT4R_HUMAN	Inhibitor	[1]

References

• [1] Brominated cyclodipeptides from the marine sponge Geodia barretti as selective 5-HT ligands. J Nat Prod. 2006 Oct;69(10):1421-4.
• [2] Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
• [3] Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501.
• [4] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [5] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [6] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [7] Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.
• [8] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [9] Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30.
• [10] Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.Schizophr Res.2012 Nov;141(2-3):144-52.
• [11] Clinical pipeline report, company report or official report of Lundbeck.
• [12] Metoclopramide stimulates catecholamine- and granin-derived peptide secretion from pheochromocytoma cells through activation of serotonin type 4 (5... Endocr Relat Cancer. 2009 Mar;16(1):281-90.
• [13] Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
• [14] Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
• [15] 5-Hydroxytryptamine mediated contractions in isolated preparations of equine ileum and pelvic flexure: pharmacological characterization of a new 5-HT(4) agonist. J Vet Pharmacol Ther. 2002 Feb;25(1):49-58.
• [16] The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol. 2008 Jul;378(1):125-37.
• [17] Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome. Drugs R D. 2008;9(1):37-63.
• [18] The effects of lintopride, a 5HT-4 antagonist, on oesophageal motility. Aliment Pharmacol Ther. 1995 Oct;9(5):563-9.
• [19] The Pharmacology of TD-8954, a Potent and Selective 5-HT(4) Receptor Agonist with Gastrointestinal Prokinetic Properties. Front Pharmacol. 2011 May 30;2:25.
• [20] A randomized trial of 5-hydroxytryptamine4-receptor agonist, YKP10811, on colonic transit and bowel function in functional constipation. Clin Gastroenterol Hepatol. 2015 Apr;13(4):701-8.e1.
• [21] Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
• [22] The inhibitory effects of tramadol on 5-hydroxytryptamine type 2C receptors expressed in Xenopus oocytes. Anesth Analg. 2004 May;98(5):1401-6, table of contents.
• [23] Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulatio... Mol Pharmacol. 2008 Mar;73(3):748-57.
• [24] Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie. 2005 Sep-Oct;60(5):441-60.
• [25] Spinal serotonin receptor activation modulates the exercise ventilatory response with increased dead space in goats. Respir Physiol Neurobiol. 2008 May 31;161(3):230-8.
• [26] Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
• [27] Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists ... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3708-12.
• [28] SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology. 2002 Sep;27(3):430-41.
• [29] Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111.